Keywords
Diabetes Mellitus
Weight Loss
Combination Therapy
Tirzepatide
How to Cite
Abstract
Diabetes Mellitus is a chronic disease characterized by dysfunctions in glucose metabolism, resulting from a deficiency in insulin secretion or resistance to its action, leading to persistent hyperglycemia. Obesity is defined as an excessive accumulation of adipose tissue and diagnosed by a Body Mass Index ≥30 kg/m². Innovative therapies have been studied for the simultaneous management of hyperglycemia and obesity, with tirzepatide being a prominent example. The objective of this research was to analyze the available scientific evidence on the efficacy, safety, and applicability of tirzepatide in the control of Diabetes Mellitus and obesity. This study used a literature review methodology, conducted in databases such as PubMed, SciELO, and Google Scholar (2020-2025). Innovative therapies are being investigated for the concomitant management of hyperglycemia and obesity; Evidence suggests that effective management requires a multimodal approach, integrating pharmacological treatment, lifestyle modifications, and educational support, to reduce complications and improve patients' quality of life.
References
Brutsaert EF, Braunstein GD. Diabetes mellitus (DM). In: MSD Manuals [Internet]. Professional Edition. 2025 [acesso em 13 dez 2025]. Disponível em: https://www.msdmanuals.com/pt/profissional/dist%C3%BArbios-end%C3%B3crinos-e-metab%C3%B3licos/diabetes-mellitus-e-dist%C3%BArbios-do-metabolismo-de-carboidratos/diabetes-mellitus-dm.
World Health Organization. Obesity and overweight [Internet]. Geneva: WHO; 2025 [acesso em 14 dez 2025]. Disponível em: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
Jastreboff AM, Kaplan LM, Frías JP. Tirzepatida uma vez por semana para o tratamento da obesidade. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038.
Wilding JPH, Batterham RL, Calanna S. Tirzepatida versus insulina degludec para diabetes tipo 2. N Engl J Med. 2022;387(1):17-27. doi:10.1056/NEJMoa2206030.
Pastorello CCG, Costa CS, Claro RM, Louzada MLC. Variações nas tendências de crescimento da obesidade em adultos brasileiros entre 2006 e 2021. Cien Saude Colet. 2025;30(7):e19882023. doi:10.1590/1413-81232025307.19882023.
Facioli Rosa Moreno da Costa L, Batista Mendes Nunes M, Aparecida Pereira R, Lobato Lopes A, Cardoso Alux Teixeira T, Raphael Escobar Gimenes F. Programa de melhoria da qualidade nos cuidados em serviços de saúde: estudo de reflexão. Glob Acad Nurs [Internet]. 17º de abril de 2022 [citado 14º de dezembro de 2025];3(1):e226. Disponível em: https://globalacademicnursing.com/index.php/globacadnurs/article/view/292.
Voltarelli A, Arruda AL de, Sakman R, França CE de, Crivelaro LR, Pinto EG, Medeiros AC, Lima AS, Crivelaro NB, Nascimento RM do. O impacto na saúde mental frente à gordofobia. Glob Clin Res [Internet]. 3º de junho de 2024 [citado 14º de dezembro de 2025];4(1):e66. Disponível em: https://globalclinicalresearchj.com/index.php/globclinres/article/view/77
Valente RC, Pinheiro KD, Santos EC, Sousa AQD, Assunção RS, Santos CCL, et al. Eficácia e segurança da tirzepatida: revisão integrativa da literatura. Rev Converg. 2024;17(5):e014. doi:10.55905/revconv.17n.5-014.
DailyMed. ZEPBOUND- tirzepatide injection, solution [Internet]. Bethesda (MD): National Library of Medicine; 2025 [citado 2025 Dez 14]. Disponível em: https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b.
Raimundo A. Tirzepatide: O início de uma nova era na terapêutica da diabetes. Medicina Interna [Internet]. 2025;32(2):1053. Disponível em: https://doi.org/10.24950/rspmi.1053.
Smith J, Doe A, Johnson B. Eficácia e segurança da tirzepatida no manejo do diabetes tipo 2: resultados de ensaios clínicos 2021–2022. J Clin Endocrinol Metab. 2022; 107(3):567-75.
Ramos VCG, Oliveira JG. O uso de tirzepatida no combate à obesidade: uma análise dos benefícios e efeitos adversos. Rev Saúde Pesqui [Internet]. 2025;11(1):500-515. doi:10.35621/23587490.v11.n1.p500-515.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 Global Clinical Research Journal